ALDA Pharmaceuticals Corp.
TSX VENTURE : APH
OTC Bulletin Board : APCSF

ALDA Pharmaceuticals Corp.

May 26, 2009 11:52 ET

ALDA Receives Approval of "T36 Disinfex" Trademark

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 26, 2009) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") has received a Notice of Allowance from the Canadian Intellectual Property Office for the trademark "T36 Disinfex". On filing of an executed Declaration of Use and payment of the prescribed registration fee, the trademark will proceed to registration.

Dr. Terrance Owen, President & CEO, comments, "We are pleased that our proposed new trademark for the Company's consumer versions of its disinfectant products has been approved by the Canadian Intellectual Property Office. The new trademark is another addition to the Company's portfolio of intellectual property. Management is committed to building the asset base of the Company and trademarks are an important part of its business."

The new trademark will be applied to consumer versions of T36® Disinfectant products, upon receipt of approval by Health Canada, and has been approved for T36 Disinfex Disinfectant Cleaner.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTC BB under the symbol APCSF.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Diane Mann
    Distribution & Sales Contact
    (604) 657-0369
    diane_mann@aldacorp.com
    www.aldacorp.com
    or
    Retail Sales
    Eastern Esthetics (ON, QU, NB, NS, PE, NL)
    902-450-2161
    or
    Retail Sales
    LCN Canada - West (MB, SK, AB, BC, NW, YK)
    780-462-2580
    or
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    604-288-7222
    syoung@freeformcom.com